PIERIS PHARMACEUTICALS INC (PIRS) Fundamental Analysis & Valuation

NASDAQ:PIRS • US7207952026

Current stock price

13.6 USD
-2.53 (-15.69%)
At close:
13.26 USD
-0.34 (-2.5%)
After Hours:

This PIRS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PIRS Profitability Analysis

1.1 Basic Checks

  • PIRS had negative earnings in the past year.
  • PIRS had a negative operating cash flow in the past year.
  • PIRS had negative earnings in each of the past 5 years.
  • PIRS had a negative operating cash flow in each of the past 5 years.
PIRS Yearly Net Income VS EBIT VS OCF VS FCFPIRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M -60M

1.2 Ratios

  • PIRS's Return On Assets of -77.74% is on the low side compared to the rest of the industry. PIRS is outperformed by 68.85% of its industry peers.
  • PIRS's Return On Equity of -98.06% is in line compared to the rest of the industry. PIRS outperforms 46.90% of its industry peers.
Industry RankSector Rank
ROA -77.74%
ROE -98.06%
ROIC N/A
ROA(3y)-42.7%
ROA(5y)-36.72%
ROE(3y)-100.33%
ROE(5y)-95.22%
ROIC(3y)N/A
ROIC(5y)N/A
PIRS Yearly ROA, ROE, ROICPIRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

  • PIRS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PIRS Yearly Profit, Operating, Gross MarginsPIRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. PIRS Health Analysis

2.1 Basic Checks

  • PIRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PIRS has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for PIRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PIRS Yearly Shares OutstandingPIRS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
PIRS Yearly Total Debt VS Total AssetsPIRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -8.87, we must say that PIRS is in the distress zone and has some risk of bankruptcy.
  • PIRS has a worse Altman-Z score (-8.87) than 71.50% of its industry peers.
  • There is no outstanding debt for PIRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.87
ROIC/WACCN/A
WACC11.91%
PIRS Yearly LT Debt VS Equity VS FCFPIRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M -60M

2.3 Liquidity

  • PIRS has a Current Ratio of 4.82. This indicates that PIRS is financially healthy and has no problem in meeting its short term obligations.
  • PIRS has a Current ratio (4.82) which is in line with its industry peers.
  • PIRS has a Quick Ratio of 4.82. This indicates that PIRS is financially healthy and has no problem in meeting its short term obligations.
  • PIRS has a Quick ratio of 4.82. This is comparable to the rest of the industry: PIRS outperforms 54.69% of its industry peers.
Industry RankSector Rank
Current Ratio 4.82
Quick Ratio 4.82
PIRS Yearly Current Assets VS Current LiabilitesPIRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. PIRS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 54.86% over the past year.
  • Looking at the last year, PIRS shows a very negative growth in Revenue. The Revenue has decreased by -97.15% in the last year.
  • Measured over the past years, PIRS shows a quite strong growth in Revenue. The Revenue has been growing by 8.03% on average per year.
EPS 1Y (TTM)54.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.86%
Revenue 1Y (TTM)-97.15%
Revenue growth 3Y13.44%
Revenue growth 5Y8.03%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.67% on average over the next years.
  • The Revenue is expected to grow by 42.76% on average over the next years. This is a very strong growth
EPS Next Y42.86%
EPS Next 2Y8.23%
EPS Next 3Y3.67%
EPS Next 5YN/A
Revenue Next Year-79.28%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y42.76%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PIRS Yearly Revenue VS EstimatesPIRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2027 2028 2029 2030 50M 100M 150M 200M
PIRS Yearly EPS VS EstimatesPIRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. PIRS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PIRS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PIRS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PIRS Price Earnings VS Forward Price EarningsPIRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PIRS Per share dataPIRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.23%
EPS Next 3Y3.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PIRS Dividend Analysis

5.1 Amount

  • No dividends for PIRS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

PIRS Fundamentals: All Metrics, Ratios and Statistics

PIERIS PHARMACEUTICALS INC

NASDAQ:PIRS (12/13/2024, 8:00:01 PM)

After market: 13.26 -0.34 (-2.5%)

13.6

-2.53 (-15.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)N/A
Inst Owners47.71%
Inst Owner Change-75%
Ins Owners0.07%
Ins Owner Change0%
Market Cap108.39M
Revenue(TTM)1.35M
Net Income(TTM)-15.95M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-85.23%
Min Revenue beat(4)-100%
Max Revenue beat(4)-43.25%
Revenue beat(8)2
Avg Revenue beat(8)14.08%
Revenue beat(12)4
Avg Revenue beat(12)34.44%
Revenue beat(16)6
Avg Revenue beat(16)33.03%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 80.17
P/FCF N/A
P/OCF N/A
P/B 6.66
P/tB 6.66
EV/EBITDA N/A
EPS(TTM)-12.61
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-3.51
FCFYN/A
OCF(TTM)-3.51
OCFYN/A
SpS0.17
BVpS2.04
TBVpS2.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -77.74%
ROE -98.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.7%
ROA(5y)-36.72%
ROE(3y)-100.33%
ROE(5y)-95.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.68%
Cap/Sales 0.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.82
Quick Ratio 4.82
Altman-Z -8.87
F-Score2
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)28.39%
Cap/Depr(5y)118.53%
Cap/Sales(3y)2.48%
Cap/Sales(5y)4.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.86%
EPS Next Y42.86%
EPS Next 2Y8.23%
EPS Next 3Y3.67%
EPS Next 5YN/A
Revenue 1Y (TTM)-97.15%
Revenue growth 3Y13.44%
Revenue growth 5Y8.03%
Sales Q2Q%-100%
Revenue Next Year-79.28%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y42.76%
EBIT growth 1Y17.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.68%
OCF growth 3YN/A
OCF growth 5YN/A

PIERIS PHARMACEUTICALS INC / PIRS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for PIERIS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to PIRS.


What is the valuation status of PIERIS PHARMACEUTICALS INC (PIRS) stock?

ChartMill assigns a valuation rating of 0 / 10 to PIERIS PHARMACEUTICALS INC (PIRS). This can be considered as Overvalued.


How profitable is PIERIS PHARMACEUTICALS INC (PIRS) stock?

PIERIS PHARMACEUTICALS INC (PIRS) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for PIRS stock?

The Earnings per Share (EPS) of PIERIS PHARMACEUTICALS INC (PIRS) is expected to grow by 42.86% in the next year.